title: [Activity of NTDs Drug-discovery Research Consortium].
abstract: Neglected tropical diseases (NTDs) are an extremely important issue facing global health care. To improve "access to health" where people are unable to access adequate medical care due to poverty and weak healthcare systems, we have established two consortiums: the NTD drug discovery research consortium, and the pediatric praziquantel consortium. The NTD drug discovery research consortium, which involves six institutions from industry, government, and academia, as well as an international non-profit organization, is committed to developing anti-protozoan active compounds for three NTDs (Leishmaniasis, Chagas disease, and African sleeping sickness). Each participating institute will contribute their efforts to accomplish the following: selection of drug targets based on information technology, and drug discovery by three different approaches (in silico drug discovery, "fragment evolution" which is a unique drug designing method of Astellas Pharma, and phenotypic screening with Astellas' compound library). The consortium has established a brand new database (Integrated Neglected Tropical Disease Database; iNTRODB), and has selected target proteins for the in silico and fragment evolution drug discovery approaches. Thus far, we have identified a number of promising compounds that inhibit the target protein, and we are currently trying to improve the anti-protozoan activity of these compounds. The pediatric praziquantel consortium was founded in July 2012 to develop and register a new praziquantel pediatric formulation for the treatment of schistosomiasis. Astellas Pharma has been a core member in this consortium since its establishment, and has provided expertise and technology in the area of pediatric formulation development and clinical development.
authors.affiliation: Medicinal Chemistry Research Labs. Drug Discovery Research, Astellas Pharma Inc.
authors.forename: Ichiji
authors.initials: I
authors.lastname: Namatame
mesh_terms: D000981:Antiprotozoal Agents; D004339:Drug Compounding; D055808:Drug Discovery / Q000379:methods / Q000458:organization & administration*; D006297:Health Services Accessibility; D006801:Humans; D058069:Neglected Diseases / Q000188:drug therapy* / Q000517:prevention & control; D010372:Pediatrics; D011223:Praziquantel; D012106:Research; D012552:Schistosomiasis / Q000188:drug therapy
chemical_list: D000981:Antiprotozoal Agents; D011223:Praziquantel